A phase II study of osimertinib in patients with poor performance status and EGFR mutation T790M-positive non-small-cell lung cancer
Not Applicable
- Conditions
- Patients with poor performance status and EGFR mutation T790M-positive non-small-cell lung cancer
- Registration Number
- JPRN-UMIN000027655
- Lead Sponsor
- Division of Thoracic Oncology, Shizuoka cancer center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 18
Inclusion Criteria
Not provided
Exclusion Criteria
1)History of using third-generation EGFR-TKI 2)Uncontrolled symptomatic brain metastasis 3)Interstitial pneumonia or pulmonary fibrosis on imaging 4)QTc > 500 msec 5)Gastrointestinal disorder 6)Uncontrollable pleural effusion , ascites or pericardial effusion 7)Receiving the radiation therapy for chest 8)28th or less days from the last dosage of immunocheckpoint therapy 9)Severe complication
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Progression free survival
- Secondary Outcome Measures
Name Time Method Safety, Response rate, Improvement rate of performance status, Overall survival